Director Daniel Janney of Krystal Biotech, Inc. (NASDAQ: KRYS) completed multiple stock transactions on February 24, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
Janney sold 37,825 shares of Krystal Biotech common stock at prices between $262.907 and $271.0938, producing aggregate proceeds of $10,113,353. In related transactions executed the same day, 13,666 shares indirectly held by Alta Bioequities, L.P. were sold at prices ranging from $263.0511 to $276.3152, for total proceeds of $6,036,029.
Also on February 24, Janney exercised options to acquire 37,895 shares of common stock at an exercise price of $2.46 per share, representing a cash outlay of $93,221 to effect the option exercise. The securities activity was carried out under a Rule 10b5-1 trading plan that Janney adopted on November 25, 2025, with the plan scheduled to terminate on November 5, 2026.
Following these transactions, Janney's direct holding in Krystal Biotech stands at 743 shares, with indirect holdings of 85,096 shares.
The insider selling took place while Krystal Biotech's share price was trading near its 52-week high of $298.30. The stock has returned approximately 59% over the prior 12 months.
Separately, publicly reported performance for the company in the fourth quarter of 2025 showed results that exceeded consensus expectations. Krystal Biotech posted earnings per share of $1.70 for Q4 2025, ahead of an analyst forecast of $1.58. Revenue for the quarter came in at $107.1 million versus an anticipated $106.16 million.
An analysis cited in the filing materials noted a PEG ratio of 0.31 for Krystal Biotech at current levels, characterizing the shares as appearing undervalued based on that metric.
Context and factual takeaways
- All transactions - the direct sale of 37,825 shares, the indirect sale of 13,666 shares via Alta Bioequities, L.P., and the option exercise for 37,895 shares - occurred on February 24, 2026, and are documented in the SEC Form 4 filing.
- The 10b5-1 plan governing the trades was adopted November 25, 2025, and is specified to terminate November 5, 2026.
- Krystal Biotech reported Q4 2025 EPS of $1.70 and revenue of $107.1 million, both above consensus projections noted in the filing materials.
The filing provides clear, verifiable detail on the quantities, price ranges, and proceeds associated with Janney's transactions, as well as the post-transaction ownership positions. The document also links the timing of sales and the option exercise to a pre-established trading plan, which is material to how the trades were authorized and structured.